25 Jun 2026 Avacta Reports Platform-Validating Data with Faridoxorubicin during BIO International Conference Investors | Therapeutics
25 Jun 2026 Avacta Announces U.S. FDA Agreement on Pivotal Trial Design for AVA6000 in Patients with Salivary Gland Cancer Investors | Therapeutics
01 Jun 2026 Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026 Investors | Therapeutics
06 May 2026 Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026 Investors | Therapeutics
21 Apr 2026 Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform Investors | Therapeutics
31 Mar 2026 Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) – a sustained-release pre|CISION® exatecan peptide drug conjugate Investors | Therapeutics